Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05232825 (ClinicalTrials.gov)	May 3, 2022	27/1/2022	A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis	A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis	Relapsing Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Ocrelizumab IV;Drug: Ocrelizumab SC;Drug: Methylprednisolone IV;Drug: Diphenhydramine IV;Drug: Dexamethasone given orally;Drug: Desloratadine given orally	Hoffmann-La Roche	NULL	Active, not recruiting	18 Years	65 Years	All	234	Phase 3	United States;Australia;Brazil;Czechia;Italy;New Zealand;Poland;Spain;Turkey;Canada;Russian Federation;Ukraine
2	NCT00674141 (ClinicalTrials.gov)	July 2008	6/5/2008	Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment	Nasal Administration of Dexamethasone for MS Treatment	MS Patient With Relpasing Remitting Attacks	Drug: Dexamethasone soduim phosphate	Hadassah Medical Organization	NULL	Withdrawn	18 Years	N/A	Both	10	Phase 1	Israel
3	EUCTR2006-003113-40-NL (EUCTR)	18/08/2006	21/07/2006	Dexamethason for the treatment of exacerbations in multiple sclerosis	Dexamethason for the treatment of exacerbations in multiple sclerosis	Multiple Sclerosis MedDRA version: 8.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis	Product Name: Dexamethason INN or Proposed INN: Dexamethasone	Department of Neurology UMCG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60		Netherlands